Repurposing Auranofin for Oncology and Beyond: A Brief Overview of Clinical Trials as Mono- and Combination Therapy

    October 2025 in “ Pharmaceuticals ”
    Doralice Giorgini, Lorenzo Chiaverini, Monica Viviano, Raffaella Belvedere, Silvia Salerno, Emma Baglini, Federico Da Settimo, Tiziano Marzo, Sabrina Taliani, Elisabetta Barresi
    TLDR Auranofin shows promise as a cancer treatment, especially when combined with other therapies.
    Auranofin (AF), traditionally used for rheumatoid arthritis, is being repurposed for oncology and other medical fields due to its ability to inhibit thioredoxin reductase and disrupt redox homeostasis, causing selective cytotoxicity in cancer cells. This review summarizes clinical trials exploring AF as both a monotherapy and in combination with other treatments, noting its safety, dosing, pharmacokinetics, and therapeutic outcomes. While most trials are in early phases (I or II), promising preclinical results and observed synergistic effects with other therapies suggest potential for AF-based treatments in addressing unmet medical needs across various pathologies.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results